Quest Diagnostics Executive Recruited to Quanterix’s Senior Management Team

Quanterix Corporation has appointed Geoff Albrecht as senior vice president and general manager of Diagnostics. This strategic hire underscores Quanterix’s commitment to transforming its Diagnostics opportunity into a key component of the company’s future growth strategy, according to company officials.

Starting with Alzheimer’s Disease Diagnostics, Albrecht will lead Quanterix’s Diagnostics strategy and the development of a comprehensive infrastructure and operational framework necessary to scale its Diagnostics portfolio into a significant revenue driver. He will report directly to CEO Everett Cunningham and become part of the executive leadership team.

“Geoff’s appointment marks a pivotal moment in Quanterix’s evolution,” Cunningham said. “We are making our Diagnostics business a fundamental pillar of our commercial strategy and future growth trajectory. We believe Geoff’s deep experience commercializing diagnostics makes him ideally suited to make Quanterix a leader in Alzheimer’s disease testing.”

Albrecht has more than 25 years of commercial leadership experience from Quest Diagnostics, where he was regional vice president for the Northeast U.S. region, managing full profit and loss responsibility for approximately $2.9 billion in revenue. Throughout his tenure at Quest, he held multiple senior leadership positions, including manager, sales director, and vice president of the North Region, where he successfully led business development initiatives, sales operations, joint venture partnerships, and merger and acquisition growth strategies.

His expertise spans strategic partnerships with health systems, health plans, physician outreach organizations, and employer groups. Albrecht has demonstrated exceptional capability in executing market strategies, optimizing operational processes, and implementing metrics-driven accountability frameworks.

In addition to his corporate responsibilities, Albrecht was a board member for UPMC and UMass joint venture partnerships, bringing valuable governance experience to his new role. He earned his bachelor of arts degree from Villanova University and will be based at Quanterix’s Billerica, Mass., headquarters.

Quanterix works to provide ultra-sensitive biomarker detection that enables breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa technology delivers sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With approximately 6,500 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,450 installed instruments. Together, the combined company offers an integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics.